A previous study evaluating clinical outcomes in patients with BRAF-mutated intrahepatic cholangiocarcinoma reported that V600E was associated with larger, more invasive tumors and poorer overall survival when compared to non-V600E mutations. This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.